{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6"},{"groupId":"OG001","value":"69.7"}]}],"title":"Hgb Improvement in patient with baseline anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"78.4"}]}],"title":"Platelet improvement in baseline thrombocytopenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"195"}],"units":"Participants"}],"description":"Proportion of subjects with hemoglobin (HgB) increase \\>=20 g/L and platelet (PLT) increase \\>=50% over baseline continuously for \\>=56 days without blood transfusions or growth factors.","groups":[{"description":"An anti-CD20 monoclonal antibody\n\nofatumumab: The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.\n\nWeek 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)","id":"OG000","title":"Ofatumumab (Arm A)"},{"description":"A Bruton Tyrosine Kinase Inhibitor\n\nibrutinib: ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity","id":"OG001","title":"Ibrutinib (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From study initiation to study closure, including up to 6 years of study follow-up","title":"Rate of Sustained Hemoglobin and Platelet Improvement","type":"SECONDARY","unitOfMeasure":"percentage of participants"}